1002 results about "Leucines" patented technology

This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

The invention discloses compound amino acid injecta, which contains arginine hydrochloride, histidine monohydrochloride, leucine, isoleucine, lysine hydrochloride and the like; meanwhile, the invention further discloses a preparation method of the compound amino acid injecta (18AA); in the event of ensuring the product quality, the compound amino acid injecta has the characteristics of saving energy and enhancing efficacy; by means of repetitive verification on precision, detection limit, quantitation limit, linear range and the like, a simple, convenient, rapid and reliable method with cleaning verification is ensured; furthermore, the residual quantity of antioxygen, namely sodium hydrogensulfite, in the compound amino acid injecta and sulphate ion generated by degrading sodium hydrogensulfite are detected according to an ion chromatography principle, thus, the amount of the antioxygen charged in the raw material proportioning can be accurately measured, and the stability of the raw material proportioning process is judged according to the measurement result; and a detection method of the compound amino acid injecta provided by the invention is an online derivative amino acid content measuring method, the speed is rapid, and the method is applied to large-scale detection.

This invention relates to combinations comprising 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gammahydroxymethylleucine)cyclosporine, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and certain nucleoside analogues, and their use in the treatment of hepatitis C virus.

The present invention discloses a topical scalp and transdermal preparation with excellent penetration to the skin and follicle, containing a [γ-hydroxy-N-methyl-L-leucine⁴] cylosporin derivative which is a non-immunosuppressive component with hair growth stimulating ability. The topical scalp and transdermal preparation is prepared by incorporating the cyclosporin derivative into a liposome, microcapsule, micro-sphere, composite particle or emulsion, capable of being employed as a hair growth stimulating agent and applied for the prevention of hair loss.

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

The invention relates to an L-2-reanal biological preparation method, which includes: utilizing L-threonine as raw materials, stirring the L-threonine in water at the temperature of 15-50 DEG C under the catalytic action of L-threonine deaminase and whole cells with a leucine dehydogenase and coenzyme regenerating function, and obtaining L-2-reanal after reaction. In the L-2-reanal biological preparation method, water is used for substituting for buffer salt solution to form a water-phase reaction system, cost of raw materials is reduced, threonine deaminase and whole cells used for catalyzing can be produced in batch by fermentation of microorganisms, are low in cost and wide in sources. Biological enzymatic catalysis reaction is water-phase reaction, transformation conditions of the enzymic method are mild, raw materials are transformed thoroughly, post-treatment is simple, products are separated by isoelectric point crystallization technology and film evaporation separation technology jointly, and the L-2-reanal biological preparation method is capable of recovering water and ammonium formate is low in cost, free of discharge of waste water and waste residues, environment-friendly in process and applicable to industrialized production of the L-2-reanal.

A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula:

• (a) (A)_n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7;
• (b) (AB)_m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and
• (c) (ABC)_p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2.

The invention relates to a composition with the efficacies of whitening, moisturizing, repairing and caring the skin, as well as a preparation method and applications of the composition. The skin care composition is prepared from the following raw materials: water, sodium hyaluronate, sodium dihydrogen phosphate dihydrate, potassium chloride, sodium hydroxide, calcium chloride, glutamine, benzalkonium chloride, magnesium sulfate, aminobutyric acid, sodium ascorbate, alanine, arginine, lysine hydrochloride, valine, histidine, leucine, taurine, coenzyme A, alcohol, polysorbate 80, thiamine, disodium diphosphate, recombinant human epidermal cell growth factors and the like. The skin care composition disclosed by the invention can permeate the muscle bottom for replenishing water for the skin from the deep layer, so that the skin is full of elasticity, the color of the skin is brightened, the fine wrinkles are reduced, the skin is clean and watery, the balance of water and oil is regulated, the pores are shrunk, meanwhile, the brightness of the face can be increased, the injured epidermal layer is effectively repaired, the activity of tyrosinase is inhibited, the generation of skin melanin is reduced, so that the skin is healthy, natural and white.

The invention relates to an amphiphilic triblock copolymer, a polymer nano-carrier preparation and preparation methods. The copolymer is a liner polymer compound containing a polyethylene glycol derivative, poly-lysine and poly-leucine, wherein one end of the poly-lysine is connected with the polyethylene glycol derivative through an amide bond, and the other end of the poly-lysine is connected with the poly-leucine through a peptide bond. The amphiphilic triblock copolymer, namely the polyethylene glycol derivative-poly-lysine-poly-leucine triblock copolymer combines the advantages of polyethylene glycol and poly-amino acid, can form a nano-carrier with a three-layer structure by self-assembly in a water solution, and can simultaneously effectively load a small molecular hydrophobic medicament, gene substances and proteins or polypeptides to form a multifunctional nano-carrier.

The invention discloses a making method of R-(+)-3-chlophenicol, which is characterized by the following: adopting left-handed bulk of chiral amino acid derivant as catalyst; synthesizing 3-chlophenicol and NaBH4 or KBH4 directly to produce R-(+)-3-chlophenicol; selecting the left-handed bulk from one of left-handed isoleucine derivant, left-handed proline derivant, left-handed tryptophan derivant, left-handed cysteine derivant, left-handed histidine derivant and left-handed methionine derivant.

The present invention provides for compositions, methods and kits for regulating energy metabolism. In one aspect, the invention provides for compositions that comprise a combination of (a) branched chain amino acids, such as leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be synergistic and/or effective for reducing weight or adipose volume. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising branched chain amino acids and vitamin B6. The invention also provides for kits comprising compositions of branched chain amino acids and vitamin B6 packaged in an oral dose form with usage instructions.

Disclosed is a method for providing amino acids in a form having improved solubility and/or improved suspension properties, and a product made by the method. The method also provides protein and amino acid compositions having decreased viscosity following heat treatment.

The invention discloses a D-amino acid oxidase mutant and application thereof. The mutant is obtained by carrying out single mutagenesis or multiple mutagenesis on a 52nd site, a 54th site, a 58th site, a 213rd site and a 335th site of amino acid with an amino acid sequence shown in SEQ ID NO.1, wherein glycine at the 52nd site is mutated into leucine, asparagine at the 54th site is mutated into valine, phenylalanine at the 58th site is mutated into glutamine, methionine at the 213rd site is mutated into serine, and serine at the 335th site is mutated into glycine. According to the D-amino acid oxidase mutant and the application thereof, a D-amino acid oxidase gene with an amino acid sequence as shown in SEQ ID NO.2 is mutated by utilizing a site-saturation mutagenesis technology, so thatthe enzyme activity and the product conversion rate are far higher than those of a wild type, and therefore the product yield in a 4-(hydroxymethylphosphoryl)-2-carbonyl-butanoic acid production process is increased.

The invention relates to a preparation method of DHA (which relates to an unsaturated fatty acid. The invention provides a preparation method of a fully synthetic medium that is suitable for high density growth of fissiparism chytrid and increases the output of the DHA. The DHA comprises a carbon source, amino acids, lysine, inorganic salts, vitamins, trace elements and water. The carbon source is glucose, the amino acids comprise alanine, methionine, cysteine, lysine, histidine, glutamic acid, glutamine, isoleucine, threonine and tryptophan; the vitamins comprise VB1, VB12, biotin, lipoic acid and folic acid; the inorganic salts comprise NaCl, KCl, MgCl2, CaCl2, Na2HPO4 and KH2PO4; and the trace elements comprise AlCl3, H3BO3, ZnSO4, MnCl2, CuSO4, FeSO4 and (NH4)6Mo7O24.4H2O. The synthetic medium is utilized for culturing the fissiparism chytrid based on a shake flask, and the output of the DHA is 9.8g/L.

The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

In various aspects, the invention provides Brassica juncea plants, seeds, cells, nucleic acid sequences and oils. Edible oil derived from plants of the invention may have significantly higher oleic acid content than other B. juncea plants. In one embodiment, the B. juncea line MJ02-357-3 contains a mutant allele MJ02-313-1/BjFAD2-a at the BjFAD2-a gene locus, having a single base-pair change (a G to A substitution in the ORF at position 281 in reference to the first ATG start codon) relative to the wild type sequence. The change is predicted to encode a Glycine-94 Aspartic acid mutation in the sequence of the predicted BjFAD2-a protein. In another embodiment, the B. juncea line MJ02-357-3 contains a mutant allele MJ02-357-3/BjFAD2-a at the BjFAD2-a gene locus, having a single base-pair change (a C to T substitution in the ORF at position 647 in reference to the first ATG start codon) relative to the wild type sequence. The change is predicted to encode a Proline-216 Leucine mutation in the sequence of the predicted BjFAD2-a protein. As a result of these mutations, it can be predicted that the function of the BjFAD2-a proteins are negatively affected in Brassica juncea lines MJ02-313-1 and MJ357-3 as reflected in the increased levels of oleic acid in seed oil in comparison with the wild-type line J96D-4830. Seeds from MJ02-313-1 and MJ02-357-3 plants may for example yield an oil having oleic acid content of greater than 70% by weight.

Disclosed is a process for preparing 5-peptide product, which comprises obtaining arginine hydrolysate, proline hydrolysate, aspartate hydrolysate, leucine hydrolysate and lysine hydrolysate through complex enzyme decomposition, employing hyperfiltration membrane to separate and reclaim 5000-1000D liquids containing rich amino acid 5-peptide molecular structures such as praline, arginine, aspartate, lycine, and leucine, then carrying out desalination, decolorization, crystallizing, embedding and drying into fine powders.

The invention discloses a composition for relieving physical fatigue and enhancing an immunologic function, a preparation method thereof and application thereof. The composite comprises 10 to 100 weight parts of guarana extract, 100 to 800 weight parts of taurine, 1 to 10 weight parts of L-lysine hydrochloride, 1 to 10 weight parts of L-isoleucine, 0.1 to 5 weight parts of L-leucine, 0.2 to 5 weight parts of L-valine, 1 to 15 weight parts of L-aspartate, 0.01 to 0.3 weight part of L-tryptophan, 0.01 to 0.3 weight part of L-phenylalanine, 0.01 to 0.3 weight part of L-threonine, 0.01 to 0.3 weight part of L-methionine, 10 to 100 weight parts of L-alanine, 10 to 100 weight parts of glycine, 1 to 15 weight parts of tea polyphenol and 1 to 20 weight parts of American ginseng extract.

The invention discloses a Omega-transaminase mutant and an application thereof. The amino acid sequence of the Omega-transaminase mutant is shown as SEQ ID NO.2. The Omega-transaminase mutant disclosed by the invention is acquired by respectively mutating isoleucine on locus 77, methionine on locus 150, histidine on locus 210 and methionine on locus 280 of aspergillus terreus Omega-transaminase into leucine, cysteine, asparaginate and cysteine. Semi-inactivation temperature (T5010) of the Omega-transaminase mutant is at 50.3 plus or minus 0.5 DEG C and is 11.8 DEG C higher than that of wild type; the half-life period (t1/2) at 40 DEG C is 114.6 plus or minus 2.8 min and is 16.6 times of that of wild type; heat stability is obviously promoted.